PFE

Pfizer raises 2020 forecast as quarterly profit beats estimates

Credit: REUTERS/CARLO ALLEGRI

Pfizer Inc beat analysts' estimates for second-quarter profit on Tuesday and raised its full-year forecast, as demand for cancer drug Ibrance and blood thinner Eliquis offset lower uptake of some of its treatments in the COVID-19 pandemic.

Adds details on quarterly profit, profit forecast, compares with estimates, share movement

July 28 (Reuters) - Pfizer Inc PFE.N beat analysts' estimates for second-quarter profit on Tuesday and raised its full-year forecast, as demand for cancer drug Ibrance and blood thinner Eliquis offset lower uptake of some of its treatments in the COVID-19 pandemic.

The company raised its 2020 adjusted profit forecast to $2.28 to $2.38 per share, compared with its prior estimate of between $2.25 and $2.35.

Pfizer and German partner BioNTech SE 22UAy.F said on Monday they would begin testing a coronavirus vaccine candidate in a late-stage study.

Pfizer's shares rose 3% to $38.69 before the opening bell.

The U.S. drugmaker said net income fell 32% to $3.43 billion in the second quarter.

Sales of Ibrance rose 7% to $1.35 billion.

Excluding items, Pfizer earned 78 cents per share, beating the average analyst estimate of 66 cents, according to IBES data from Refinitiv.

Sales fell to $11.80 billion from $13.26 billion.

(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)

((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780, outside U.S. +91 806749 2709;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PFE

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More